Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

作者： R. M. Bukowski , C. M. Baum , S. T. Kim , R. J. Motzer , T. E. Hutson